Top Markets
#1 Islamic Coin Islamic Coin +151.22%
#2 Akedo Akedo +76.34%
#3 Velvet Velvet +52.62%
#4 Glidr Glidr +51.75%
#5 DOVU DOVU +47.94%
#6 Black Phoenix Black Phoenix +33.93%
#7 Cross Cross +31.13%
#8 Cap Cap +21.55%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.55%
#10 DoubleZero DoubleZero +14.82%
Coin of the day
Islamic Coin Islamic Coin
Настройки
Язык
Pусский
Валюта
USD
Тема
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Ранг среди акций #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Цена акции
$0.11725176
Последняя синхронизация: 2025-07-14
Рыночная капитализация
$481.50K
Изменение (1 день)
-0.20%
Изменение (1 год)
0.00%
Страна
FR
Торговля PHAXIAM Therapeutics S.A. (PHXM)

Категория

Healthcare
Выручка компании PHAXIAM Therapeutics S.A. (PHXM)
Выручка на Jun 2024 TTM: $2.30M
Согласно последним финансовым отчетам PHAXIAM Therapeutics S.A., текущая выручка компании (TTM) составляет $2.30M. В 2022 году компания получила выручку $7.13M больше, чем выручке в 2021 году, которая составила $4.75M. Выручка — это общий доход, который компания получает от продажи товаров или услуг. В отличие от прибыли, расходы не вычитаются.
История выручки PHAXIAM Therapeutics S.A. с 2016 по 2026
Выручка на конец каждого года
Год Выручка Изменить
2026 (TTM) $2.30M 56.82%
2023 $1.47M -79.44%
2022 $7.13M 50.00%
2021 $4.75M 4.97%
2020 $4.53M -23.61%
2019 $5.93M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Выручка аналогичных компаний или конкурентов
Компания Выручка Разница в выручке Страна
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 549,098.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 261,845.69%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B 439,752.28%
BE